T1	intervention 9 18	denosumab
T2	eligibility 437 546	postmenopausal, aromatase inhibitor-treated patients with early-stage hormone receptor-positive breast cancer
T3	control 814 821	placebo
T4	location 888 895	Austria
T5	location 900 906	Sweden
T6	outcome-Measure 1350 1400	time from randomisation to first clinical fracture
T7	duration 1824 1863	Between Dec 18, 2006, and July 22, 2013
T8	No-of-participants 1865 1869	3425
T9	No-of-participants 1926 1930	3420
T10	intervention-participants 1984 1988	1711
T11	control-participants 2004 2008	1709
T12	outcome 2134 2165	time to first clinical fracture
T13	outcome 2239 2258	number of fractures
T14	intervention-value 2283 2285	92
T15	control-value 2314 2317	176
T16	outcome 2634 2661	incidence of adverse events
T17	intervention-value 2793 2797	1366
T18	intervention-value 2806 2809	80%
T19	control-value 2834 2838	1334
T20	control-value 2847 2850	79%
T21	adverse-effect 2962 2972	arthralgia
T22	adverse-effect 2983 3019	aromatase-inhibitor related symptoms
T23	outcome 3281 3285	died
T24	intervention-value 3313 3316	one
T25	outcome 2865 2898	numbers of serious adverse events
T26	intervention-value 2900 2903	521
T27	control-value 2907 2910	511
T28	intervention-value 2912 2915	30%
